Harmful Drug Exposure
Harmful Drug Exposure Lawyer
For a free, confidential legal consultation, submit your Harmful Drug Exposure injury claim or call 1-800-471-3980 now.
If you are looking for a firm that can handle Harmful Drug Exposure lawsuits, or are simply unsure if you have a case, there is no obligation to discuss your case with one of GPW's attorneys. Contact us today.
About Harmful Drug Exposure
November 14th, 2007. (Press Release) The U.S. Food and Drug Administration announced today that the manufacturer of Avandia (rosiglitazone), a drug used to treat type 2 diabetes, has agreed to add new information to the existing boxed warning in the drug's labeling about potential increased risk for heart attacks.
People with type 2 diabetes who have ... [More >>]
July 17th, 2007. A new study published in the Annals of Internal Medicine finds that most type-2 diabetics are better off using older, cheaper diabetes drugs than their heavily advertised, newer counterparts. With the exception of those who cannot tolerate specific drugs like Glucophage (metformin), the effectiveness of the older medications was on ... [More >>]
June 29th, 2007. One million type two diabetics in the US, and nearly 6 million worldwide, who take Avandia (rosiglitazone maleate) may be putting themselves at an increased risk of heart attack.
Earlier this spring, The New England Journal of Medicine released a study by Dr. Steven Nissen that analyzed the combined results ... [More >>]
May 21st, 2007. (Press Release) The U.S. Food and Drug Administration (FDA) is aware of a potential safety issue related to Avandia (rosiglitazone), a drug approved to treat type 2 diabetes. Safety data from controlled clinical trials have shown that there is a potentially significant increase in the risk of heart attack and heart-related deaths ... [More >>]
March 15th, 2007.
Drugs included in the label warning update are the following 13 products:
Ambien/Ambien CR (Sanofi Aventis)
Butisol Sodium (Medpointe Pharm HLC)
Carbrital (Parke-Davis)
Dalmane (Valeant Pharm)
Doral ... [More >>]
March 14th, 2007. (Press Release) The U.S. Food and Drug Administration (FDA) has requested that all manufacturers of sedative-hypnotic drug products, a class of drugs used to induce and/or maintain sleep, strengthen their product labeling to include stronger language concerning potential risks. These risks include severe allergic reactions and complex sleep-related behaviors, which may include ... [More >>]
July 28th, 2006. Injured by Zyprexa? Side effects of this antipsychotic drug include diabetes, weight gain, hyperglycemia, pancreatitis, and diabetic ketoacidosis.
Zyprexa Risks
The following are the risks and side effects associated with Zyprexa therapy. This list is not exhaustive. From the FDA web site, Zyprexa's risks include:
A life-threatening nervous system ... [More >>]
December 9th, 2005. An editorial appearing Thursday December 9, 2005 in The New England Journal of Medicine called into question the information provided by Merck for a key study about cardiovascular events caused by the arthritis drug Vioxx. The study called into question was published in November of 2000 for the VIGOR ... [More >>]
August 19th, 2005.
Have a Vioxx legal claim? For a free, confidential legal consultation, Submit your Vioxx injury claim or call 1-800-471-3980 now.
Of Note:
Actual damages: $24.4 Million
Punitive Damages: $229 Million
$229 Million is the amount Merck made in sales of Vioxx from Oct. 2001, when FDA suggested the label change, to the ... [More >>]
June 9th, 2005. (Press Release) Eli Lilly and Company announced today that it has entered into an agreement in principle with plaintiffs' attorneys involved in Zyprexa liability litigation to settle a majority of the claims against Lilly relating to the medication.
When finalized, the settlement will resolve the majority ... [More >>]
|
[site map] |
